Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., has relocated its US headquarters to the ON3 Campus at 200 Metro Blvd. in Nutley. This move offers employees a dynamic, technologically advanced work environment that further enables Eisai’s commitment to innovation and the pursuit of its human health care (hhc) mission to deliver life-changing therapies and health-related solutions to help people live healthier and more fulfilling lives.
Eisai’s headquarters will bring approximately 800 jobs to the Nutley/Clifton area and, at full capacity, the new facility will accommodate 1,300 employees. The company’s U.S. presence also includes three early-stage discovery research centers, as well as commercial, clinical development and global demand organizations.
“Eisai’s decision to relocate to the ON3 Campus is a demonstration of our ongoing commitment to New Jersey and to be part of this diverse life sciences hub,” said Tatsuyuki Yasuno, president, Eisai Inc. & Americas Region. “With a 400-seat auditorium and an Innovation Center at our new US headquarters, we are establishing dedicated space and resources to educate and motivate our employees, as well as a forum to hear from patients, advocacy partners and the community. Through this collaboration, we can make a positive impact on people and society and fulfill our human health care mission.”
“We recently met with the leadership of Eisai, and we were extremely impressed,” said Township of Nutley Mayor Mauro G. Tucci. “Eisai is a global pharmaceutical company, committed to human health care, who values the communities where they work. We welcome Eisai to Nutley and look forward to working with them to enhance our Township. We thank them for their investment in our community and the surrounding area.”
“New Jersey has established itself as the global epicenter of the biopharmaceutical industry, and we are proud to see an innovative company like Eisai call Clifton home,” said James Anzaldi, Mayor, City of Clifton. “Given the urgency for new treatments for cancer and neurologic conditions, we look forward to seeing the important work Eisai is doing make a positive societal impact and improve the lives of our residents and people around the world.”
To access more business news, visit NJB News Now.Related Articles: